[25-NSE] iTeos Therapeutics, Inc. SEC Filing
Nasdaq has submitted a Form 25 notifying the SEC of the removal of iTeos Therapeutics, Inc. (ITOS) from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office at 321 Arsenal Street, Watertown, Massachusetts and provides a contact phone number. The form states the Exchange and the issuer have complied with applicable rule provisions governing withdrawal or removal, but the specific rule selection box, signature and date fields are not completed in the provided content.
Nasdaq ha inviato un Modulo 25 alla SEC per notificare la rimozione di iTeos Therapeutics, Inc. (ITOS) dalla quotazione e/o registrazione sul Nasdaq Stock Market LLC. Il documento indica la sede principale dell'emittente in 321 Arsenal Street, Watertown, Massachusetts e riporta un numero di telefono per i contatti. Nel modulo si afferma che la Borsa e l'emittente hanno rispettato le disposizioni di regolamento applicabili alla revoca o alla rimozione, ma i campi relativi alla selezione della norma applicata, alla firma e alla data non risultano compilati nel contenuto fornito.
Nasdaq ha presentado un Formulario 25 ante la SEC para notificar la eliminación de iTeos Therapeutics, Inc. (ITOS) de la cotización y/o registro en Nasdaq Stock Market LLC. La presentación identifica la oficina principal del emisor en 321 Arsenal Street, Watertown, Massachusetts y facilita un número de teléfono de contacto. El formulario indica que la Bolsa y el emisor han cumplido las disposiciones normativas aplicables a la retirada o exclusión, pero los campos específicos de selección de norma, firma y fecha no aparecen completados en el contenido proporcionado.
나스닥은 iTeos Therapeutics, Inc.(ITOS)를 Nasdaq Stock Market LLC에서 상장 및/또는 등록 해제하는 사실을 SEC에 통지하는 Form 25를 제출했습니다. 제출서에는 발행인의 본사가 매사추세츠주 워터타운 321 Arsenal Street에 있다고 기재되어 있으며 연락용 전화번호가 제공되어 있습니다. 해당 양식에는 거래소와 발행인이 상장 철회 또는 삭제에 관한 적용 규정을 준수했다고 명시되어 있으나, 적용 규정 선택란과 서명 및 날짜란은 제공된 내용에서 작성되지 않았습니다.
Le Nasdaq a déposé un formulaire 25 auprès de la SEC pour notifier le retrait d'iTeos Therapeutics, Inc. (ITOS) de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dépôt indique le siège principal de l'émetteur au 321 Arsenal Street, Watertown, Massachusetts, et fournit un numéro de téléphone de contact. Le formulaire précise que la Bourse et l'émetteur ont respecté les dispositions applicables régissant le retrait ou la radiation, mais les cases relatives au choix de la règle applicable, ainsi que les champs de signature et de date, n'apparaissent pas complétés dans le contenu fourni.
Die Nasdaq hat bei der SEC ein Formular 25 eingereicht, um die Entfernung von iTeos Therapeutics, Inc. (ITOS) von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC mitzuteilen. Die Einreichung nennt den Firmensitz des Emittenten in der 321 Arsenal Street, Watertown, Massachusetts, und enthält eine Kontakttelefonnummer. Das Formular besagt, dass die Börse und der Emittent die anwendbaren Regelungen für den Rückzug oder die Streichung eingehalten haben, jedoch sind das Feld zur Auswahl der konkreten Regel, die Unterschrift und das Datumsfeld im vorliegenden Inhalt nicht ausgefüllt.
- Exchange and issuer compliance language is included indicating adherence to referenced procedural rules
- Notice of removal/delisting of iTeos Therapeutics (ITOS) from Nasdaq is indicated, which is material to shareholders
- Signature, date, and specific rule-selection fields are not completed in the provided content, limiting confirmation of execution and timing
Insights
TL;DR: Nasdaq filed to remove ITOS from listing; the form indicates procedural compliance but lacks signature/date.
The filing is a formal notification that Nasdaq seeks removal of iTeos Therapeutics' securities from the exchange and asserts compliance with the procedural requirements of the Exchange Act rules referenced. The document includes issuer identification and exchange name but omits which specific subsection was checked and omits the signing party and date. From a listings-compliance perspective, the filing meets the requirement to notify the SEC, yet the absence of a completed signature block and explicit rule selection in the provided text limits confirmation of whether the removal is voluntary or initiated by the Exchange.
TL;DR: The notice signals delisting/withdrawal action for ITOS; procedural language is present but key execution details are missing in the excerpt.
The document shows Nasdaq certifying it has reasonable grounds to file Form 25 for iTeos Therapeutics and references compliance with rules governing withdrawal/removal. For governance review, the filing is material because removal from an exchange affects shareholder liquidity and reporting status. However, the provided content lacks the executed signature and date and does not specify the precise rule provision selected, which constrains assessment of timing and voluntariness.
Nasdaq ha inviato un Modulo 25 alla SEC per notificare la rimozione di iTeos Therapeutics, Inc. (ITOS) dalla quotazione e/o registrazione sul Nasdaq Stock Market LLC. Il documento indica la sede principale dell'emittente in 321 Arsenal Street, Watertown, Massachusetts e riporta un numero di telefono per i contatti. Nel modulo si afferma che la Borsa e l'emittente hanno rispettato le disposizioni di regolamento applicabili alla revoca o alla rimozione, ma i campi relativi alla selezione della norma applicata, alla firma e alla data non risultano compilati nel contenuto fornito.
Nasdaq ha presentado un Formulario 25 ante la SEC para notificar la eliminación de iTeos Therapeutics, Inc. (ITOS) de la cotización y/o registro en Nasdaq Stock Market LLC. La presentación identifica la oficina principal del emisor en 321 Arsenal Street, Watertown, Massachusetts y facilita un número de teléfono de contacto. El formulario indica que la Bolsa y el emisor han cumplido las disposiciones normativas aplicables a la retirada o exclusión, pero los campos específicos de selección de norma, firma y fecha no aparecen completados en el contenido proporcionado.
나스닥은 iTeos Therapeutics, Inc.(ITOS)를 Nasdaq Stock Market LLC에서 상장 및/또는 등록 해제하는 사실을 SEC에 통지하는 Form 25를 제출했습니다. 제출서에는 발행인의 본사가 매사추세츠주 워터타운 321 Arsenal Street에 있다고 기재되어 있으며 연락용 전화번호가 제공되어 있습니다. 해당 양식에는 거래소와 발행인이 상장 철회 또는 삭제에 관한 적용 규정을 준수했다고 명시되어 있으나, 적용 규정 선택란과 서명 및 날짜란은 제공된 내용에서 작성되지 않았습니다.
Le Nasdaq a déposé un formulaire 25 auprès de la SEC pour notifier le retrait d'iTeos Therapeutics, Inc. (ITOS) de la cotation et/ou de l'enregistrement sur le Nasdaq Stock Market LLC. Le dépôt indique le siège principal de l'émetteur au 321 Arsenal Street, Watertown, Massachusetts, et fournit un numéro de téléphone de contact. Le formulaire précise que la Bourse et l'émetteur ont respecté les dispositions applicables régissant le retrait ou la radiation, mais les cases relatives au choix de la règle applicable, ainsi que les champs de signature et de date, n'apparaissent pas complétés dans le contenu fourni.
Die Nasdaq hat bei der SEC ein Formular 25 eingereicht, um die Entfernung von iTeos Therapeutics, Inc. (ITOS) von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC mitzuteilen. Die Einreichung nennt den Firmensitz des Emittenten in der 321 Arsenal Street, Watertown, Massachusetts, und enthält eine Kontakttelefonnummer. Das Formular besagt, dass die Börse und der Emittent die anwendbaren Regelungen für den Rückzug oder die Streichung eingehalten haben, jedoch sind das Feld zur Auswahl der konkreten Regel, die Unterschrift und das Datumsfeld im vorliegenden Inhalt nicht ausgefüllt.
FAQ
What action does this Form 25 notify for iTeos Therapeutics (ITOS)?
Does the filing state whether the removal is voluntary or initiated by Nasdaq?
What issuer contact information is included for ITOS in the filing?
Are the rule provisions that support the removal identified in the form?
Is there a signed and dated certification in the provided content?
